Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Novartis sees brain-atrophy data as an edge for MS pill Gilenya

01.05.2014 / Fierce Pharma

Fresh off winning European backing for broader use–which could prompt more multiple sclerosis patients to switch–Gilenya's ability to protect patients' brains is at center stage at this week's American Academy of Neurology meeting.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: